To see the issue content and the abstract you do not have to login

Please login to download the full articles

If you do not have a subscription to Rhinology please consider to take one.

Click here to become a member of the European Rhinologic Society and a subscriber to the journal `RHINOLOGY`, beginning 2020. Subscription including membership fee: Euro 139.-

If you only want to buy this paper please click here
The price of the paper is 25 EUR.

Omalizumab in patients with NSAIDs-exacerbated respiratory disease

Volume: 58 - Issue: 3

Firstpage: 226 - Lastpage: 232

U. Forster-Ruhrmann - D. Stergioudi - G. Pierchalla - J.W. Fluhr - K.-C. Bergmann - H. Olze

BACKGROUND: The association of acetylsalicylic acid (ASA) intolerance, chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, or chronic urticaria is known as NSAID-exacerbated respiratory disease (N-ERD). N-ERD patients often suffer from recurrent nasal polyps, severe asthma or also from urticaria. The aim of the present study was to retrospectively analyze the clinical efficacy of anti-IgE antibody treatment with omalizumab in patients with confirmed N-ERD.
METHODS: In the open trial with patients receiving verum patients with CRSwNP, confirmed N-ERD by oral or nasal ASA challenges, asthma or chronic urticaria were included in the study. Rhinological and pulmonary parameters were evaluated before and after 3, 6 and 9 months of therapy by rhinological questionnaires (CRS VAS-scores and RSOM-31), nasal polyp (NP)-, ACT-scores and FEV1 values. Urticaria activity was monitored clinically. N-ERD patients with aspirin desensitization were included as control group (follow-up 9 months).
RESULTS: In the omalizumab group 16 patients were included (10 female, 6 male, mean age 51 yrs). CRS symptoms, RSOM-31- and NP-score decreased significantly following omalizumab therapy compared to baseline. The ACT-score (MV 16.5 to 20.6) and FEV1values (MV 80 % to 89 %) improved significantly. No urticaria symptoms were reported after 3 months. Oral prednisolone therapy was required in one case and a repeated nasal sinus surgery in an additional case due to progression of NP. In the control group (8 female, 8 male, mean age 45 yrs) the NP-score was unchanged.
CONCLUSIONS: Omalizumab is an effective therapy option in N-ERD patients in a 9 month study period.

U. Forster-Ruhrmann - D. Stergioudi - G. Pierchalla - J.W. Fluhr - K.-C. Bergmann - H. Olze - Omalizumab in patients with NSAIDs-exacerbated respiratory disease

Rhinology 58-3: 226-232, 2020